Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Bibiana Bielekova, Nancy Richert, Thomas Howard, Gregg Blevins, Silva Markovic-Plese, Jennifer McCartin, Jens Würfel, Joan Ohayon, Thomas A. Waldmann, Henry F. McFarland, Roland Martin

Research output: Contribution to journalArticle

Abstract

Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-β therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

Original languageEnglish (US)
Pages (from-to)8705-8708
Number of pages4
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number23
DOIs
StatePublished - Jun 8 2004
Externally publishedYes

ASJC Scopus subject areas

  • Genetics
  • General

Fingerprint Dive into the research topics of 'Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β'. Together they form a unique fingerprint.

  • Cite this

    Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J., Würfel, J., Ohayon, J., Waldmann, T. A., McFarland, H. F., & Martin, R. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proceedings of the National Academy of Sciences of the United States of America, 101(23), 8705-8708. https://doi.org/10.1073/pnas.0402653101